Latest News

Hologic projections lower-than-expected annual sales on devices shipping stop

Medical technology company Hologic said on Monday it expects annual profits second-rate experts' price quotes, injured by ongoing momentary time out on shipping of its bone density scanning machines.

The Marlborough, Massachusetts-based company makes and provides viral load tests, molecular diagnostics assays, medical imaging systems and surgical items focused on women's. health.

Shares of the business fell 2.05% to $82 in extended trading.

The business anticipates 2025 revenue in range of $4.15 billion to $4.20 billion, second-rate. experts' price quote of $4.21 billion.

The company stated its full-year forecast consisted of an anticipated effect from continuous short-term. stop in shipping of its bone density scanning maker, Horizon DXA systems.

Sales for the skeletal health business-- that includes X-ray systems and other products. that aid with minimally invasive surgical procedures-- totalled $12.7 million, below analysts'. price quotes of $15.1 million, according to data compiled by LSEG.

However, the company anticipates to resume shipping of Horizon DXA systems in the latter half of. very first quarter.

The current IV fluid scarcity from typhoons will hurt the business's elective breast and. surgical procedures, impacting its diagnostics products sale, Hologic's CFO Karleen Oberton said. in the earnings call.

Hologic likewise anticipated annual adjusted earnings per share in range of $4.25-$ 4.35, with its. mid-point in line with analysts' expectations.

On an adjusted basis, Hologic posted a revenue of $1.01 per share, in line with experts'. quotes. Hologic also beat sales expectations for the fourth quarter.

(source: Reuters)